LRP1B and cancer: In our datasets, the TMB rates in samples with LRP1B mutations tended to fall into the medium or high categories, and further analysis of 25 independent cancer types verified this outcome, thereby suggesting that LRP1B mutations may be a good biomarker for immune intervention.